Literature DB >> 33392469

Undifferentiated prostate cancer treated with docetaxel.

Masaki Kobayashi1, Minato Yokoyama1, Masaharu Inoue1, Yasuhisa Fujii1.   

Abstract

INTRODUCTION: Undifferentiated prostate cancer is a rare and aggressive disease, and no definitive therapeutic strategy for metastatic undifferentiated prostate cancer has been established. CASE
PRESENTATION: We report the case of a 70-year-old man with undifferentiated prostate cancer and lymph node metastases. Following the patient's progression after platinum-based chemotherapy, we initiated treatment with docetaxel, which resulted in a partial response. The patient was alive for 42 months after initiation of docetaxel, maintaining relatively good quality of life with minimal hospital stay.
CONCLUSION: Docetaxel may be a good therapeutic option for metastatic undifferentiated prostate cancer.
© 2020 The Authors. IJU Case Reports published by John Wiley & Sons Australia, Ltd on behalf of the Japanese Urological Association.

Entities:  

Keywords:  chemotherapy; docetaxel; prostate cancer; quality of life; undifferentiated carcinoma

Year:  2020        PMID: 33392469      PMCID: PMC7770600          DOI: 10.1002/iju5.12162

Source DB:  PubMed          Journal:  IJU Case Rep        ISSN: 2577-171X


  10 in total

1.  High efficacy of concomitant treatment of undifferentiated (anaplastic) thyroid cancer with radiation and docetaxel.

Authors:  Marlene Troch; Oskar Koperek; Christian Scheuba; Karin Dieckmann; Martha Hoffmann; Bruno Niederle; Markus Raderer
Journal:  J Clin Endocrinol Metab       Date:  2010-06-30       Impact factor: 5.958

2.  Undifferentiated carcinoma of the prostate with small cell features: immunohistochemical subtyping and reflections on histogenesis.

Authors:  B Helpap; J Köllermann
Journal:  Virchows Arch       Date:  1999-05       Impact factor: 4.064

3.  The feasibility study of docetaxel in patients with anaplastic thyroid cancer.

Authors:  Kenji Kawada; Koichi Kitagawa; Sachi Kamei; Megumi Inada; Ayako Mitsuma; Masataka Sawaki; Toyone Kikumori; Yasushi Fujimoto; Hiroshi Arima; Tsuneo Imai; Yuichi Ando
Journal:  Jpn J Clin Oncol       Date:  2010-03-03       Impact factor: 3.019

Review 4.  Atypical case of metastatic undifferentiated prostate carcinoma in a 36 years old man: clinical report and literature review.

Authors:  M D'Aprile; D Santini; S Di Cosimo; G Gravante; B Vincenzi; S Spoto; S Costantino; C Rabitti; G Tonini
Journal:  Clin Ter       Date:  2000 Sep-Oct

5.  S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trial.

Authors:  Yong Sang Hong; Young Suk Park; Ho Yeong Lim; Jeeyun Lee; Tae Won Kim; Kyu-pyo Kim; Sun Young Kim; Ji Yeon Baek; Jee Hyun Kim; Keun-Wook Lee; Ik-Joo Chung; Sang-Hee Cho; Kyung Hee Lee; Sang Joon Shin; Hye Jin Kang; Dong Bok Shin; Sook Jung Jo; Jae Won Lee
Journal:  Lancet Oncol       Date:  2012-10-10       Impact factor: 41.316

6.  Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.

Authors:  Daniel P Petrylak; Catherine M Tangen; Maha H A Hussain; Primo N Lara; Jeffrey A Jones; Mary Ellen Taplin; Patrick A Burch; Donna Berry; Carol Moinpour; Manish Kohli; Mitchell C Benson; Eric J Small; Derek Raghavan; E David Crawford
Journal:  N Engl J Med       Date:  2004-10-07       Impact factor: 91.245

7.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.

Authors:  Ian F Tannock; Ronald de Wit; William R Berry; Jozsef Horti; Anna Pluzanska; Kim N Chi; Stephane Oudard; Christine Théodore; Nicholas D James; Ingela Turesson; Mark A Rosenthal; Mario A Eisenberger
Journal:  N Engl J Med       Date:  2004-10-07       Impact factor: 91.245

Review 8.  [A case of liver metastasis from gastric cancer responding completely to S-1/docetaxel chemotherapy].

Authors:  Hirokazu Kitahara; Eiji Oki; Hiroki Saeki; Koji Ando; Ken Shirabe; Shunji Kounoe; Shinichi Aishima; Yoshihiro Kakeji; Yoshihiko Maehara
Journal:  Gan To Kagaku Ryoho       Date:  2013-08

9.  Docetaxel and cisplatin in first line treatment of patients with unknown primary cancer: a multicenter study of the Anatolian Society of Medical Oncology.

Authors:  Umut Demirci; Ugur Coskun; Halit Karaca; Faysal Dane; Nuriye Yildirim Ozdemir; Arife Ulas; Meltem Baykara; Mustafa Benekli; Metin Ozkan; Suleyman Buyukberber
Journal:  Asian Pac J Cancer Prev       Date:  2014

10.  Immunohistochemical profile for unknown primary adenocarcinoma.

Authors:  Kenji Hashimoto; Yuko Sasajima; Masashi Ando; Kan Yonemori; Akihiro Hirakawa; Koh Furuta; Hitoshi Tsuda; Yasuhiro Fujiwara
Journal:  PLoS One       Date:  2012-01-27       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.